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Aims: Our study addressed potential associations between fatty liver and small, dense low-density lipoprotein
cholesterol (sd-LDL-C) levels using a cross-sectional analysis.
Methods: We enrolled 476 male subjects. Serum sd-LDL-C concentrations were determined using precipitation
assays.
Results: Subjects were divided into four groups based on triglyceride (TG) and LDL-C levels: A, TG< 150 mg/dl and
LDL-C< 140 mg/dl; B, TG< 150 mg/dl and LDL-C≥ 140 mg/dl; C, TG≥ 150 mg/dl and LDL-C< 140 mg/dl; and D,
TG≥ 150 mg/dl and LDL-C≥ 140 mg/dl. sd-LDL-C levels and the prevalence of fatty liver were significantly higher in
groups B, C, and D than in group A. Subjects were also categorized into four groups based on serum sd-LDL-C
levels; the prevalence of fatty liver significantly increased with increasing sd-LDL-C levels. Additionally, logistic
regression analysis revealed an independent association between sd-LDL-C concentrations and fatty liver using
such potential confounders as obesity and hyperglycemia as variables independent of elevated TG or LDL-C levels.
Conclusions: Fatty liver is a significant determinant of serum sd-LDL-C levels independent of the presence of
obesity or hyperglycemia. Fatty liver may alter hepatic metabolism of TG and LDL-C, resulting in increased sd-LDL-C
levels.
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Atherogenic lipid profiles in patients with metabolic syn-
drome or glucose intolerance are characterized by hyper-
triglyceridemia, elevated apolipoprotein B levels, reduced
high-density lipoprotein cholesterol (HDL-C) concentra-
tions, and an increased proportion of small, dense low-
density lipoprotein (sd-LDL) particles [1-3]. Compared
with large LDL, sd-LDL particles show increased pene-
tration of the arterial wall, lower affinity for the LDL re-
ceptor, longer half-life in plasma, greater susceptibility to
glycation, and lower resistance to oxidative stress, sug-
gesting that sd-LDL is highly atherogenic [4,5]. Indeed,* Correspondence: yasushii@po.synapse.ne.jp
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distribution, and reproduction in any mediumpatients with high levels of sd-LDL particles were shown
to have an approximately 3-fold increase in the risk of
developing coronary heart disease compared with indivi-
duals with primarily large, buoyant LDL particles [6]. In
addition, the sd-LDL-C concentration has been suggested
to be a better surrogate marker than the LDL-C con-
centration for the severity of coronary heart disease [7].
The presence of fatty liver is an independent predictor
of coronary heart disease [8-10]. In addition, fatty liver is
a manifestation of metabolic syndrome, and is associated
with obesity, type 2 diabetes mellitus (T2DM), and
hypertriglyceridemia [11]. In patients with T2DM or
metabolic syndrome, fatty liver may enhance atherogen-
esis by increasing levels of sd-LDL particles [12,13]. The
precise role of fatty liver in the pathogenesis of sd-LDL,
however, is still unclear. In the present study, weentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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men to examine potential associations between the fatty
liver and sd-LDL levels.
Materials and methods
Four hundred seventy-six Japanese men who received
regular health checkup in 2004 or 2005 participated in
the study. Subjects were not taking medication for dysli-
pidemia and/or diabetes mellitus, and had serum trigly-
ceride (TG) levels less than 400 mg/dl. This study was
conducted at Kagoshima Kouseiren Medical Health Care
Center, and was approved by the ethics committee of
the Kagoshima Prefectural Federation of Agricultural
Cooperatives for Health and Welfare.
Fatty liver diagnoses were made using ultrasonog-
raphy (SSA-250A and SSA-700A, Toshiba, Ibaraki,
Japan; Logic 400, GE Yokogawa, Tokyo, Japan) based on
findings of a bright liver (increased echogenicity) with
liver − kidney contrast (increased echogenicity of the
liver compared with the right kidney). Body mass index
(BMI) was calculated using the standard equation: body
weight (kg)/height2 (m2). Obesity was defined as BMI
values ≥ 25 kg/m2. Venous blood samples were obtained
from all subjects before 9:00 am after an overnight fast
and analyzed immediately. Alanine aminotransferase
(ALT) and γ-glutamyl transpeptidase (γ-GTP) activities
and serum concentrations of total cholesterol (TC), TG,
and glucose were measured using standard laboratory pro-
cedures. HDL-C levels were determined using detergents
and direct homogeneous assays of serum samples (Daiichi
Chemicals, Takaoka, Japan). sd-LDL-C levels were deter-
mined using a previously described method with minor
modifications [14,15] and a commercially available assay
kit (sd-LDL SEIKEN, Denka Seiken Co., Tokyo, Japan).
Subjects with TG levels≥ 400 mg/dl were excluded from
this study. LDL-C concentrations were calculated using
the Friedewald formula: LDL-C (mg/dl) =TC (mg/dl)−
HDL-C (mg/dl)−TG (mg/dl)/5. Serological testing for
hepatitis B surface antigen (HBs Ag) and hepatitis C virus
antibodies (HCV Ab) was performed using an enzyme im-
munoassay and enzyme-linked immunosorbent assay,
respectively.
Patients were defined as hypertension based on sys-
tolic blood pressure ≥ 130 mmHg, diastolic blood pres-
sure ≥ 85 mmHg, or if they were taking medication for
hypertension. Hyperglycemia or diabetes was identified
based on fasting blood glucose levels≥ 110 mg/dl or ≥ 126
mg/dl, respectively. Hypertriglyceridemia and elevated
levels of LDL-C were defined as TG levels≥ 150 mg/dl
and LDL-C levels≥ 140 mg/dl, respectively [16]. A com-
mon questionnaire was used by a public health nurse to
assess each subject’s history of alcohol intake and smok-
ing status. Current alcohol consumption was defined as
daily alcohol intake of≥ 20 g/day.Statistical analysis
Continuous variables were analyzed using t-tests or ana-
lysis of variance (ANOVA), and categorical variables
were examined using chi-square tests. Multiple compari-
sons among the differences were examined using Dunnett’s
or Ryan’s method. Maximum likelihood of odds ratios
for fatty liver risk and 95% confidence intervals (95%
CIs) were calculated using logistic regression models.
All presented P values are two-sided. P values< 0.05
were considered significant. Statistical analyses were per-
formed using JMP version 7 (SAS Corp, Cary, NC, USA)
and R version 2.13.0.
Results
Characteristics of the subjects, clinical parameters, and
relationships to the presence of fatty liver
Subject demographics, clinical parameters, and associa-
tions with fatty liver are summarized in Table 1. Among
476 subjects, 190 (39.9%) were diagnosed with fatty liver
(Table 1). The mean concentration [95% CI] of sd-LDL-C
among all subjects was 44.6 mg/dl [43.1− 46.2]. The pre-
valences of hyperglycemia and diabetes were 29.0% and
8.0%, respectively.
Of note, the lipid profiles of subjects with fatty liver
were typically atherogenic (Table 1); the concentrations
of TC, TG, LDL-C, sd-LDL-C, and apolipoprotein B
were significantly higher in the group with fatty liver
than in the subjects without fatty liver. In addition, the
concentration of HDL-C was significantly lower in the
fatty liver group than in the subjects without fatty liver.
Subjects with fatty liver were significantly younger
than those without fatty liver (Table 1). BMI values, the
prevalence of obesity, serum glucose concentrations, and
the prevalence of hyperglycemia were significantly
higher in the fatty liver group compared to the subjects
without fatty liver. No significant differences were noted
between the groups in the prevalence of hypertension,
current alcohol consumption, and smoking status.
Contributions of hypertriglyceridemia and elevated levels
of LDL-C to serum sd-LDL-C concentrations and the
prevalence of fatty liver
Features of four groups categorized based on the pres-
ence of elevated LDL-C levels (≥ 140 mg/dl) and/or
hypertriglyceridemia (≥ 150 mg/dl) are shown in Table 2.
sd-LDL-C concentrations were higher in the group with
only elevated levels of LDL-C (group B; P< 0.001) and
the group with only hypertriglyceridemia (group C;
P< 0.001) compared with the control group (group A).
Additionally, sd-LDL-C concentrations in the group
with elevated levels of LDL-C and hypertriglyceridemia
were the highest among the groups (Group D; P< 0.001
compared with the control group). Compared with the
control group, the groups with hypertriglyceridemia had
Table 1 Characteristics of the study subjects
Overall Fatty liver (−) Fatty liver (+) P values
(476) (286) (190) Fatty liver (−) vs.(+)
Age (years) 55.9 [55.1−56.8] 57.8 [56.5−58.9] 53.2 [51.9−54.4] < 0.001
BMI (kg/m2) 24.2 [23.9−24.5] 23.1 [22.7−23.4] 25.9 [25.5−26.3] < 0.001
Obesity (% of subjects) 37.0 23.8 56.8 < 0.001
Blood glucose (g/dl) 106.8 [105.2−108.4] 104.5 [102.4−106.5] 110.2 [107.7−112.8] < 0.001
Hyperglycemia (% of subjects) 29.0 24.5 35.8 0.008
TG (mg/dl) 132.5 [125.9−139.2] 112.6 [104.5−120.7] 162.6 [152.7−172.5] <0.001
HDL-C (mg/dl) 55.7 [54.5−56.9] 58.0 [56.4−59.6] 52.2 [50.5−53.9] < 0.001
LDL-C$ (mg/dl) 130.2 [127.6−132.9] 127.4 [124.1−130.7] 134.5 [130.1−138.8] 0.010
TC (mg/dl) 212.4 [209.5−215.3] 208.0 [204.3−211.7] 219.1 [214.4−223.9] < 0.001
sd-LDL-C (mg/dl) 44.6 [43.1−46.2] 40.8 [38.9-42.8] 50.5 [48.0-53.0] < 0.001
Apolipoprotein B (mg/dl) 97.8 [96.−99.6] 93.2 [91.0−95.4] 104.6 [101.9−107.3] < 0.001
ALT (IU/L) 28.1 [26.4−29.7] 22.7 [20.8−24.6] 36.1 [33.7−38.5] < 0.001
γ-GTP (IU/L) 45.4 [41.2−49.5] 36.9 [31.7−42.1] 58.0 [51.6−64.4] < 0.001
Hypertension (% of subjects) 54.8 52.5 58.4 0.200
Current alcohol consumption (%) 37.8 40.2 34.2 0.186
Smoking status (% of subjects) (never/former/current) 31.5/39.9/28.6 31.8/39.5/28.7 31.1/40.5/28.4 0.974
Data are expressed as means [95% CIs] or percentages.
$, LDL-C levels were calculated using the Friedwald formula.
Continuous variables were compared by t-test and categorical variables were compared by Chi-square test.
Hosoyamada et al. Diabetology & Metabolic Syndrome 2012, 4:34 Page 3 of 7
http://www.dmsjournal.com/content/4/1/34higher proportions of sd-LDL-C (group C and group D;
both P< 0.001), whereas group B did not show a signifi-
cant difference (P= 0.766).
No significant differences were observed between
groups A and B in BMI values (P= 0.719), the prevalence
of obesity, serum glucose levels (P= 0.838), and the
prevalence of impaired fasting glucose levels. The preva-
lence of fatty liver in group B (P= 0.001), however, was
significantly higher than in group A. No significant dif-
ference between groups A and B was noted for the
concentration of HDL-C (P= 0.235). BMI values were
significantly higher in group C than in group A (P=0.001).
The prevalence of obesity was higher in group C than in
group A, although the difference was not significant
(Ryan’s method).
The mean ages (P = 0.024), blood glucose levels
(P = 0.021), and rates of hyperglycemia (P = 0.006)
significantly differed in groups A and C. Further-
more, the prevalence of fatty liver was significantly higher
in group C than in group A (P< 0.001). The concetration
of HDL-C was lower in group C than in group A
(P< 0.001).
Compared with group A, group D had higher BMI values
(P< 0.001), blood glucose concentrations (P< 0.001), and
rates of obesity (P=0.003), hyperglycemia (P=0.003), and
fatty liver (P< 0.001), whereas the mean age (P< 0.001)
and HDL-C concentration (P< 0.001) were lower.Independent association between fatty liver and
sd-LDL-C levels
The subjects were classified into four groups based on
serum sd-LDL-C concentrations: ≤ 21.1 mg/dl, 21.2–
42.7 mg/dl, 42.8–55.7 mg/dl, and≥ 55.8 mg/dl. Character-
istics of the groups are summarized in Table 3. Among
these groups, the concentrations of TG, LDL-C, TC, and
apolipoprotein B increased significantly and the HDL-C
concentration decreased significantly as sd-LDL-C levels
increased. BMI values and the rates of fatty liver and
hyperglycemia increased significantly with increasing sd-
LDL-C levels. No significant association was detected be-
tween sd-LDL-C levels and the prevalence of hyperten-
sion, current alcohol consumption, or current smoking.
As shown in Table 4, logistic regression analysis re-
vealed an independent association between sd-LDL-C
levels and the presence of fatty liver using BMI values,
the presence of hyperglycemia, and other potential con-
founders as variables. This association remained when the
analysis was performed only with subjects who did not
have elevated levels of LDL-C (subjects in groups A and
C from Table 2) or with those who did not have hypertri-
glyceridemia (subjects in groups A and B from Table 2).
Discussion
This study provides important information about the re-
lationship between fatty liver and LDL particle size. We
Table 2 Comparison of groups categorized based on the presence of elevated LDL-C levels and hypertriglyceridemia
Elevated LDL-C levels/
hypertriglyceridemia
Group A Group B Group C Group D P
value(−)/(−) (n = 216) (+)/(−) (n = 120) (−)/(+) (n = 95) (+)/(+) (n = 45)
Lipid profiles
TG (mg/dl) 91.1 [85.1−96.7] 98.1 [90.5−105.6] 229.3 [220.8−237.8] 219.0 [206.7−231.4] < 0.001
HDL-C (mg/dl) 59.3 [57.6−61.1] 56.8 [54.4−59.1] 49.3 [46.7−52.0] 48.9 [45.1−52.7] < 0.001
LDL-C (mg/dl) 114.2 [111.8−116.7] 162.5 [159.2−165.8] 112.1 [108.4−115.8] 159.1 [153.8−164.5] < 0.001
Sd-LDL-C (mg/dl) 33.8 [31.9−35.6] 49.6 [47.2−52.1] 51.9 [49.2−54.7] 68.5 [64.5−72.5] < 0.001
Sd-LDL-C/LDL-C 0.30 [0.28−0.31] 0.30 [0.29−0.32] 0.47 [0.45−0.48] 0.43 [0.40−0.46] < 0.001
TC (mg/dl) 191.8 [188.7−194.8] 238.9 [234.8−243.1] 207.3 [202.7−212.0] 251.8 [245.1−258.6] < 0.001
Apolipoprotein B (mg/dl) 82.8 [75.5−80.4] 112.6 [110.3−114.9] 99.4 [96.8−102.0] 126.3 [122.5−130.1] < 0.001
Demographics, clinical characteristics, and laboratory data
Age (years) 57.4 [56.2−58.7] 56.1 [54.4−57.8] 54.3 [52.4−56.3] 51.5 [48.7−54.3] < 0.001
BMI (kg/m2) 23.6 [23.2−24.0] 24.0 [23.4−24.5] 25.1 [24.5−25.7] 25.7 [24.8−26.6] < 0.001
Obesity (% of subjects) 31.0 30.8 46.3 62.2 < 0.001
Glucose (mg/dl) 103.8 [101.4−106.1] 105.2 [102.1−108.4] 113.5 [110.0−117.1] 111.5 [106.4−116.7] < 0.001
Hyperglycemia
(% of subjects) 22.7 27.5 37.9 44.4 0.004
ALT (IU/L) 24.3 [22.0−26.6] 27.4 [24.3−30.5] 34.4 [30.9−37.9] 34.6 [29.5−39.6] < 0.001
γ-GTP (IU/L) 35.3 [29.4−41.2] 38.6 [30.7−46.5] 70.0 [61.2−78.9] 59.6 [46.8−72.5] < 0.001
Fatty liver (% of subjects) 25.9 43.3 61.1 53.3 < 0.001
Hypertension
(% of subjects) 53.7 54.2 57.9 55.6 0.919
Current alcohol consumption
(% of subjects) 38.4 54.2 46.3 33.3 0.153
Current smokers
(% of subjects) 28.7 30.0 28.4 24.4 0.919
Data are expressed as means [95% CIs] or percentages.
$, LDL-C levels were calculated using the Friedwald formula.
Continuous variables were compared by ANOVA and categorical variables were compared by Chi-square tests.
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ence of fatty liver and serum sd-LDL-C levels, including
after we adjusted for such potential confounders as BMI
and impaired fasting glucose levels. It may be problem-
atic to discuss visceral obesity and insulin resistance only
based on BMI and impaired fasting glucose levels, re-
spectively. Toledo and colleagues, however, showed a re-
lationship between fatty liver and sd-LDL size in
patients with T2DM [12]. Sugeno and colleagues sug-
gested that fatty liver synergistically interacts with meta-
bolic syndrome to affect sd-LDL-C levels [13]. Based on
these studies and the data present here, fatty liver
appears to affect LDL particle size, an effect that may be
independent of visceral obesity and systemic insulin re-
sistance. Thus, treating fatty liver may decrease athero-
genesis in the patients with metabolic syndrome or
T2DM by reducing sd-LDL-C levels.
The composition of TG and cholesterol esters in LDL
particles is modified through interactions with TG-richlipoproteins and cholesterol ester transfer protein
(CETP); the molecules are sequentially hydrolyzed by
lipoprotein lipase, resulting in the generation of sd-LDL
particles [1]. Therefore, elevated LDL-C levels and hyper-
triglyceridemia seem to be the causative dyslipidemia of
sd-LDL particles formation. Tokuno and colleagues
reported that statin and fibrate decrease sd-LDL-C con-
centrations in patients with T2DM via different mechan-
isms: the former does not affect the sd-LDL-C/LDL-C
ratio, whereas the latter reduces this ratio [17]. In the
present study, sd-LDL-C concentrations were signifi-
cantly elevated in subjects with elevated LDL-C levels
and normal TG levels, although the sd-LDL-C/LDL-C
ratio did not increase. In contrast, sd-LDL-C concentra-
tions and the sd-LDL-C/LDL-C ratio were elevated in
subjects with normal LDL-C levels and hypertriglyceride-
mia (Table 2). Notably, fatty liver was significantly more
common in both of these groups. In addition, as shown
in Table 4, an independent association between fatty liver
Table 3 Characteristics of groups categorized based on serum sd-LDL-C concentrations
Characteristics Quartiles of serum sd-LDL-C concentrations (mg/dl)
≤ 21.1 (n = 119) 21.2 - 42.7 (n = 119) 42.8 - 55.7 (n = 118) 55.8 (n = 120) P value
Lipid profiles
TG (mg/dl) 83.8 [72.6−95.1] 111.8 [100.5−123.1] 145.3 [134.0−156.7] 188.7 [177.5−200.0] < 0.001
HDL-C (mg/dl) 63.5 [61.2−65.8] 57.6 [55.3−59.8] 52.7 [50.4−55.0] 49.0 [46.7−51.3] < 0.001
LDL-C$ (mg/dl) 110.3 [105.7−115.0] 125.9 [121.2−130.6] 135.9 [131.2−140.5] 148.6 [144.0−153.3] < 0.001
TC (mg/dl) 190.6 [185.6−195.7] 205.8 [200.8−210.9] 217.7 [212.6−222.8] 235.4 [230.4−240.4] < 0.001
Apolipoprotein B (mg/dl) 78.0 [75.5−80.4] 91.9 [89.4−94.4] 103.5 [101.0−105.9] 117.6 [115.1−120] < 0.001
Demographics, clinical characteristics, and laboratory data
Age (years) 57.9 [56.1−59.6] 56.8 [50.1−58.6] 55.3 [53.6−57.1] 53.8 [52.0−55.5] 0.007
BMI (kg/m2) 23.4 [22.8−23.9] 24.0 [23.4−24.5] 24.5 [24.0−25.1] 25.0 [24.4−25.5] < 0.001
Obesity (% of subjects) 30.3 30.3 39.8 47.5 0.017
Glucose (mg/dl) 105.0 [101.8−108.2] 105.6 [103.0−106.2] 10.6.2 [103.8−108.6] 110.4 [105.9−115.0] 0.080
Hyperglycemia
(% of subjects) 20.2 28.6 30.5 36.7 0.045
ALT (IU/L) 22.4 [19.3−25.5] 26.5 [23.3−29.6] 29.1 [26.0−32.3] 34.3 [31.2−37.4] < 0.001
γ-GTP (IU/L) 31.9 [23.8−39.9] 40.5 [32.4−48.6] 47.0 [38.9−55.1] 62.0 [53.9−70.0] < 0.001
Fatty liver (% of subjects) 23.5 34.5 44.0 57.5 < 0.001
Hypertension
(% of subjects) 52.2 52.1 53.4 61.7 0.380
Current drinking
(% of subjects) 39.5 39.5 39.8 32.5 0.587
Current smoking
(% of subjects) 23.5 32.8 25.4 32.5 0.262
Data are expressed as means [95% corresponding intervals] or percentages.
$, LDL-C levels were calculated using the Friedwald formula.
Continuous variables were compared by ANOVA and categorical variables were compared by Chi-square tests.
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analysis was performed using only subjects without ele-
vated LDL-C levels (subjects in groups A and C from
Table 2) or those without hypertriglyceridemia (subjects
in groups A and B from Table 2). Therefore, fatty liver
appears to independently affect LDL particle size owing,
at least in part, to impaired hepatic metabolism of TG
and LDL-C. The concentration of sd-LDL-C wereTable 4 Association between fatty liver and sd-LDL-C levels
Quartiles
Characteristics ≤ 21.1 21.2 - 42.7
All subjects 1 (referent) 1.59 [0.85−3.20]
Subsets of subjects
HBs-Ag (−), HCV-Ab(−)# 1 (referent) 1.83 [0.85−4.05]
Elevated LDL-C levels (−) ## 1 (referent) 1.60 [0.79−3.26]
Hypertriglyceridemia (−) ### 1 (referent) 1.14 [0.57−2.29]
Risk of fatty liver was estimated by logistic regression analysis using sd-LDL-C levels
current smoking as covariables. Data are expressed as odds ratios [95% correspond
#, Subjects were 385 men who were negative for both HBs-Ag and HCV-Ab. ##, Subj
were 336 men who did not show hypertriglyceridemia.highest in the group with elevated LDL-C levels and
hypertriglyceridemia (group D from Table 2), suggesting
that the effects of impaired metabolism of TG and LDL-C
may be additive.
Visceral obesity and insulin resistance have been
recognized as major causes of increased levels of sd-LDL
particles, because these factors are major contributors
to postprandial hypertriglyceridemia; one underlyingof serum sd-LDL-C concentrations (mg/dl)
42.8 - 55.7 ≥ 55.8 P value for trend
1.96 [1.05−3.69] 2.48 [1.32−4.70] 0.001***
2.50 [1.18−5.43] 3.60 [1.73−7.77] 0.001***
1.95 [0.92−4.16] 2.89 [1.29−6.62] 0.009***
1.55 [0.76−3.23] 2.25 [1.00−5.10] 0.018***
, age, BMI, hypertension, hyperglycemia, current alcohol consumption, and
ing intervals]. P values for trend were obtained using the likelihood ratio test.
ects were 311 men who did not have elevated levels of LDL-C. ###, Subjects
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pocytes, which stimulates hepatic TG output. Addition-
ally, if a fatty liver is present, upregulated de novo
synthesis of fatty acids may increase hepatic TG produc-
tion. Donnely et al. reported that approximately 60% of
fat that accumulates in the liver and is incorporated into
lipoprotein is derived from circulating free fatty acids,
and nearly 25% results from de novo lipid synthesis in
patients with nonalcoholic fatty liver disease (NAFLD)
[18]. In addition to altered TG output, fatty liver has
been shown to be associated with increased TG content
per very-low-density lipoproteins (VLDL) particle which
is defined as large VLDL [12,19]. Large VLDL efficiently
promotes modification of LDL particles via CETP. Re-
cent studies revealed that the liver X receptor (LXR)-
sterol regulatory element-binding protein (SREBP)-1c
pathway governs the size of VLDL particles secreted by
the liver [20,21]. It is noteworthy that the LXR-SREBP-1c
pathway is a major causative factor of fatty liver, because
several genes involved in de novo fatty acid synthesis are
expressed in response to upregulated LXR-SREBP-1c sig-
naling [22]. Thus, fatty liver affects VLDL particles quan-
titatively and qualitatively, resulting in increased sd-LDL
formation.
Interestingly, the LXR-SREBP-1c pathway is a key
regulator of not only fatty acid metabolism but also
cholesterol metabolism [23,24]. Activation of the LXR-
SREBP-1c pathway by increased intrahepatic cholesterol
levels stimulates cholesterol secretion in VLDL and sup-
pression of LDL uptake. Enhanced de novo synthesis of
cholesterol in livers of patients with NAFLD [25] may
increase intrahepatic cholesterol concentrations. Excess
intake of dietary cholesterol has been observed in patients
with NAFLD [26]. We previously showed a positive inde-
pendent association between the presence of fatty liver
and serum cholesterol levels in men [27]. Thus, we believe
that fatty liver is independently associated with elevated
serum LDL-C levels owing to altered cholesterol metabol-
ism that results in increased sd-LDL-C levels.
The activities of CETP and hepatic lipase may correl-
ate with sd-LDL-C levels [28]. Lipoprotein lipase is re-
sponsible for an important step in TG clearance.
Prolonged accumulation of TG-rich remnants following
meals may also be associated with postprandial dyslipi-
demia. Thus, further studies are needed to clarify the
role of fatty liver in elevated levels of sd-LDL particles.
Of note, our study has several limitations. First, the associ-
ation between fatty liver and sd-LDL-C was examined with
multivariate analysis using age, BMI, hypertension, hyper-
glycemia, current alcohol consumption [29], smoking sta-
tus [30], and sd-LDL-C levels as covariables. It is possible,
however, that additional factors that we did not analyze
may have affected the results. For example, we did not en-
roll women subjects, which may have skewed the results[30]. Second, the diagnosis of fatty liver was made using
abdominal ultrasonography, which identifies fatty steatosis.
Ultrasonography may not detect a subset of advanced al-
cohol or nonalcoholic fatty liver diseases—referred to as
burnt-out steatohepatitis—which are characterized by less
fatty steatosis.
Conclusion
Fatty liver may affect the hepatic metabolism of TG and/
or LDL-C, resulting in increased serum sd-LDL-C levels
and accelerated atherogenesis in patients with metabolic
syndrome or T2DM. Therefore, fatty liver should be
treated, especially if patients present with metabolic syn-
drome or T2DM. Further studies, however, are needed
to develop effective treatment strategies for fatty liver.
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